ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025
Healthcare access, symptom burden, and psychological impact in hypertrophic cardiomyopathy: a multinational patient-driven survey.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Addressing discrepancies in symptom and psychosocial assessments in hypertrophic cardiomyopathy.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Hypertrophic cardiomyopathy (HCM) is a complex genetic heart disease with significant clinical, psychological, and socioeconomic implications. While research has focused on pathophysiology and treatment, patient-reported experiences remain underexplored. Methods: A cross-sectional, multinational online survey was distributed between December 2024 and February 2025, targeting individuals diagnosed with HCM in Europe. The questionnaire included sections on demographics, symptom burden, impact on daily life, medical management, and psychological well-being. Data were analyzed descriptively, with subgroup analyses based on geography, employment, and healthcare access. Results: A total of 337 qualifying participants from 18 European countries completed the survey. They were mainly diagnosed because of symptoms (107, 42 %). Specifically, shortness of breath and fatigue had an overall high impact on quality of life, both at diagnosis and at the time of survey (3.09/5 vs 2.93/5; 3.23/5 vs 3.46/5, respectively). With HCM diagnosis, the proportion of patients engaged in low to moderate activities increased significantly (87 % vs 50 %, p < 0.01) and one major psychological complaint was weight gain (71, 49 %). Twenty-two (15 %) patients reported having lost their job because of HCM; 46 (14 %) reported a limitation in working hours as well as limitation in the kind of work performed (32, 9 %), due to the disease. Despite a significant psychological burden access to mental health support was limited, as only 15 % of patients regularly consulted a psychologist. Conclusions: This survey highlights critical gaps in HCM management, including healthcare accessibility, persistent symptom burden, and unmet psychological needs. Improved care pathways, mental health integration, and workplace accommodations are essential to enhance patient-centered HCM management across Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.